The advent of sodium-glucosecontransporter 2 inhibitors (SGLT2i), glucagon-like peptide-1 (GLP1) agonists,and angiotensin receptor/neprilysin inhibitors (ARNI) in cardiovascular diseasehas raised the exciting potential for these therapies in PAH [113]. The gene discussed is GCG; the disease is pulmonary arterial hypertension.